Re: JMP chat
Thatís all well and good, but doesnít matter if efficacy isnít there as well. I think they can check the box on safety but is that in spite of efficacy?
Itís disappointing that numerous clinical data originally slated for the current quarter has seemingly been pushed to 2024. Do you think they will even attend JPM this year? Not sure that they will have anything new to say. Could see them giving an interim update on the phase 2 2012 data potentially.
The stock price desperately needs a catalyst, otherwise I could see it drifting to a $1 or lower once again.